Core Viewpoint - The Schall Law Firm is investigating Abacus Global Management, Inc. for potential violations of securities laws, particularly concerning misleading statements and undisclosed information [1][2]. Group 1: Investigation Details - The investigation centers on whether Abacus issued false or misleading statements and failed to disclose critical information to investors [2]. - A report by Morpheus Research claims that Abacus changed its portfolio valuation methodology to present a more favorable financial picture, suggesting that the company is involved in an accounting scheme related to life settlements [2]. Group 2: Company Background - Abacus Global Management is identified as a SPAC (Special Purpose Acquisition Company) with a valuation of $794 million [2]. - The report also raises concerns about the methodologies used by Abacus to estimate life expectancy, indicating potential irregularities in their calculations [2]. Group 3: Legal Representation - The Schall Law Firm is reaching out to shareholders who may have suffered losses and is offering free consultations regarding their rights [3].

Core Viewpoint - Abacus Global Management strongly refutes the allegations made in a short seller's report, asserting that the claims regarding its reliance on a single life expectancy provider and inflated balance sheet valuation are incorrect [2][22]. Group 1: Response to Short Seller Allegations - The short seller's report claims that Abacus relies too heavily on Lapetus Solutions for life expectancy estimates, which the company denies, stating that it does not depend on Lapetus for portfolio valuation [2][6]. - Abacus engaged Lewis and Ellis, a third-party actuarial firm, to validate its policy balance sheet, confirming that the valuation of $449 million as of March 31, 2025, aligns closely with its own reported valuation of $446 million [9][6]. - The company emphasizes that its valuation methodology incorporates a mark-to-market approach, which is based on actual market transactions rather than solely on life expectancy estimates [12][10]. Group 2: Valuation Methodology - Abacus employs a dual valuation approach: life expectancy estimates for consumer-facing transactions and market-based valuations for balance sheet management, ensuring fair pricing and accurate asset valuation [10][11]. - The company prioritizes market reality in its trading portfolio, which allows for a more accurate reflection of asset value based on actual transaction history [20][12]. - Recent market transactions support the accuracy of Abacus's valuation model, with the company selling 226 policies for $141.4 million, closely matching the estimated balance sheet value of $139.1 million [15][16]. Group 3: Shareholder Commitment and Future Outlook - Abacus executives and shareholders collectively own approximately 46% of the outstanding shares, with a two-year lock-up period expiring on July 3, 2025, which is expected to positively impact the company's inclusion in the Russell 2000 and 3000 indices [17][19]. - The company asserts that the expiration of the lock-up period is not an opportunity for large shareholders to cash out but rather a chance to drive the company towards its next milestones [18][19]. - Abacus is committed to transparent communication with shareholders regarding any future share sales, emphasizing its long-term dedication to increasing shareholder value [20][21].

SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Abacus Global Management, Inc. (NASDAQ: ABL) focused on whether Abacus Global and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist in the Abacus Global investigation or if you are an Abacus Global investor who suff ...

Core Viewpoint - Abacus Global Management has authorized a $20 million share repurchase program, reflecting confidence in its business model and balance sheet amidst a short attack on its stock price [1][2]. Group 1: Share Repurchase Program - The share repurchase program is effective from June 5, 2025, and will last for up to 18 months [1]. - The company may repurchase shares through various methods, including open market transactions and block trades, at its discretion based on several factors [2]. - The program is expected to be funded using cash on hand and anticipated future free cash flow [2]. Group 2: Management's Response - The CEO of Abacus stated that the current depressed share price presents a buying opportunity, supported by the new share repurchase program and employee investments totaling over $2 million [2]. - The company is committed to pursuing legal action against those responsible for the short attack [3]. Group 3: Company Overview - Abacus Global Management specializes in alternative asset management, data-driven wealth solutions, and technology innovations, focusing on longevity-based assets and personalized financial planning [8].

Company Overview - Abacus Global Management, Inc. operates as an alternative asset manager and market maker [3] Investigation Details - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Abacus Global, focusing on whether the company and its executives made false or misleading statements or failed to disclose material information to investors [1] - The investigation follows a report published by Morpheus Research, which accused Abacus Global of engaging in an accounting scheme related to life settlements, leading to a significant drop in stock price [3] Market Reaction - Following the publication of the Morpheus Research report, Abacus Global's stock price fell by more than 21% [3]

Core Insights - Holzer & Holzer, LLC is investigating Abacus Global Management, Inc. for potential violations of federal securities laws following a report by Morpheus Research alleging that the company's returns are artificially inflated through questionable accounting practices [1] - The report claims that Abacus employs a "mark to model" accounting scheme that resembles past failures in the life settlements industry, leading to a decline in the company's stock price [1] Company Overview - Abacus Global Management, Inc. is publicly traded on NASDAQ under the ticker ABL [1] - The company is currently facing scrutiny due to allegations of asset overvaluation and non-compliance with securities regulations [1] Legal Context - Holzer & Holzer, LLC is a law firm specializing in securities litigation, with a history of representing shareholders and recovering significant amounts for those affected by corporate misconduct [3] - The firm has been recognized as a top-rated securities litigation law firm for the years 2021, 2022, and 2023 [3]

ORLANDO, Fla., June 04, 2025 (GLOBE NEWSWIRE) -- Abacus Global Management, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a leader in the alternative asset management space, today provided the following response to a false and misleading short attack. Abacus has been buying and selling life insurance policies for over two decades with long-standing and trusted counter-party relationships. If Abacus used flawed data causing over-valuation of the underlying insurance product assets, the Company would be goin ...

BOSTON, June 04, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Abacus Global Management, Inc. (Nasdaq: ABL) for potential securities law violations. Investors who have lost money in their Abacus Global Management, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/abl. What is this all about? Shares of Abacus fell over 15% in intraday trading on June 4, 2025, after Morpheus Research published a r ...

Core Viewpoint - Abacus Life, Inc. (ABL) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with stock price movements, particularly due to institutional investors adjusting their valuations based on these estimates [4][6]. - For the fiscal year ending December 2025, Abacus Life, Inc. is projected to earn $0.76 per share, reflecting a 15.2% increase from the previous year, with a 2% rise in the Zacks Consensus Estimate over the past three months [8]. Zacks Rating System - The Zacks Rank stock-rating system categorizes stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [7]. - The upgrade of Abacus Life, Inc. to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].

Core Viewpoint - Abacus Life, Inc. (ABL) shares have increased by 7.5% recently, with a mean price target of $13.70 suggesting a potential upside of 57.5% from the current price of $8.70 [1] Price Targets and Analyst Estimates - The mean estimate consists of five short-term price targets with a standard deviation of $1.10, indicating variability among analysts [2] - The lowest price target of $12 suggests a 37.9% increase, while the highest target of $15 indicates a potential surge of 72.4% [2] - A low standard deviation signifies a strong agreement among analysts regarding the stock's price direction [9] Earnings Estimates and Analyst Sentiment - Analysts are optimistic about ABL's earnings prospects, as indicated by upward revisions in EPS estimates, which correlate with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 1% over the past month, reflecting two upward revisions and one downward revision [12] - ABL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting strong potential for upside [13]